- United States
XBiotech Full Year 2022 Earnings: US$1.08 loss per share (vs US$0.58 loss in FY 2021)
XBiotech (NASDAQ:XBIT) Full Year 2022 Results
Key Financial Results
- Net loss: US$32.9m (loss widened by 89% from FY 2021).
- US$1.08 loss per share (further deteriorated from US$0.58 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
XBiotech shares are up 2.4% from a week ago.
We don't want to rain on the parade too much, but we did also find 2 warning signs for XBiotech (1 is a bit concerning!) that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether XBiotech is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
Flawless balance sheet with weak fundamentals.